Overcoming Regulatory Challenges in Cognitive Drug Development

Feb 9, 2015

In recent years, numerous pharmaceutical and biotechnology companies have undertaken development programmes intended to assess the efficacy of various pro-cognitive drugs on a wide variety of cognitive domains across several psychiatric and neurologic conditions. Henry J. Riordan, PhD, Executive Vice ...

Read More